Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 9,101–9,200 of 15,747
Stein, M., Grossman, Z., Brosh‐Nissimov, T., Gottesman, B., Shahar, A., Wechsler, E., Matz, E., Cohen, O., Alroy‐Preis, S., & Anis, E. (2021) · Acta Paediatrica · doi:10.1111/apa.16226 · Cited by 4
Wu, Q., Shen, Y., Xie, L., Zhang, J., Qiu, Z., Tang, M., & Chen, L. (2022) · Journal of Cardiac Surgery · doi:10.1111/jocs.17205 · Cited by 4
Systematic analyses of the resistance potential of drugs targeting SARS-CoV-2 main protease
(2023) · doi:10.1101/2023.03.02.530652 · Cited by 5
“Multiple strategies have been implemented to reduce the spread of the virus and disease progression, including mRNA vaccines (Polack et al. 2020), monoclonal antibody therapeutics (Chen et al. 2021), and most recently small molecule direct acting antivirals (Owen et al. 2021; Beigel et al. 2020;…”
BackgroundZavaglio, F., Cassaniti, I., Sammartino, J. C., Tonello, S., Sainaghi, P. P., Novelli, V., Meloni, F., Lilleri, D., & Baldanti, F. (2022) · Microorganisms · doi:10.3390/microorganisms10061250 · Cited by 4
“The mRNA vaccine BNT162b2 [15] was approved after showing safety and a 95% efficacy in preventing COVID-19 [16].”
BackgroundÖzgür, D., & Tütüncü, E. E. (2022) · Mikrobiyoloji Bulteni · doi:10.5578/mb.20229904 · Cited by 6
COVID‐19 vaccination: are more jabs needed or are we now immune?
Giles, M., & Flanagan, K. L. (2024) · Internal Medicine Journal · doi:10.1111/imj.16341 · Cited by 3
Measuring the impact of the COVID-19 vaccine rollout
Peate, I. (2021) · Independent Nurse · doi:10.12968/indn.2021.2.25 · Cited by 5
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine
Waxman, J. G., Magen, O., & Hernán, M. Á. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2206926 · Cited by 6
Harada, D., Tamura, T., Ninomiya, K., Kubo, T., Kuyama, S., Tachibana, S., Inoue, K., Chikamori, K., Kudo, K., Ochi, N., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14737 · Cited by 3
“The SARS-CoV-2 vaccine has a high incidence of side effects such as fever even in healthy individuals, however, there are few serious adverse events.(9,10) Patients with chronic inflammatory diseases receiving immunosuppressive treatment experience the same side effects from vaccines as those of healthy individuals.”
BackgroundMethodAli, K. M., Rashid, P. M. A., Ali, K. M., Mahmood, K. I., & Rostam, H. M. (2024) · Central European Journal of Immunology · doi:10.5114/ceji.2024.136382 · Cited by 5
“Their development and deployment offer a powerful tool in curbing the spread of SARS-CoV-2 and mitigating the impact of the pandemic [19].”
BackgroundMartínez-Subiela, S., Franco‐Martínez, L., Rubio, C. P., Muñoz-Prieto, A., Torres-Cantero, A. M., Tecles, F., Sánchez-Resalt, C., Cerón, J. M. C., & Tvarijonaviciute, A. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-0418 · Cited by 7
“Both induce antibodies to the SARS-CoV-2 S-protein, including neutralizing antibodies (Nabs) [22, 23], leading in our report to a significant increase of IgGs at T2 in serum in all vaccinated individuals followed by a significant decrease in T3.”
BackgroundSeroconversion after COVID-19 vaccine in a dialysis patient on immunosuppressants
Alfano, G., Fontana, F., Mori, G., et al. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab065 · Cited by 5
SARS-CoV-2 Neutralizing Antibodies in Mexican Population: A Five Vaccine Comparison
Alcorta-Núñez, F., Pérez-Ibave, D. C., Burciaga-Flores, C. H., Garza, M., González-Escamilla, M., Rodríguez-Niño, P., González-Guerrero, J. F., Alcorta-Garza, A., Vidal-Gutiérrez, Ó., Ramirez‐Correa, G. A., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13061194 · Cited by 8
Infantino, M. G., Tsalouchos, A., Russo, E., Laudicina, S., Grossi, V., Lari, B., Benucci, M., Stacchini, L., Amedei, A., Casprini, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012333 · Cited by 5
“of Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) mRNA vaccines; therefore, safety and efficacy data are lacking in this population [8,9].”
BackgroundMonschein, T., Zrzavy, T., Löbermann, M., Winkelmann, A., Berger, T., Rommer, P. S., Hartung, H., & Zettl, U. K. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01155-4 · Cited by 4
“Insgesamt wurden bisher 14 neue Impfstoffe zugelassen, die sich gegen SARSCoV-2 richten [4, 11, 34, 50, 51, 59, 77, 85, 92].”
BackgroundChen, D., Pan, Y., Wang, Y., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.11.012 · Cited by 5
“The inclusion criteria ere as follows: (1) The study was a prospective or retrospective ohort study; (2) Studies have evaluated the serological response f patients with solid malignancies to COVID-19 vaccine and the redictors of poor seroconversion; (3) Corresponding RRs and 95% onfidence intervals (CIs) are available.”
MethodSafety of coronavirus disease 2019 vaccines in 213 adult patients with sickle cell disease
Joseph, L., Corbasson, A., Manceau, S., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18547 · Cited by 5
The Impact of COVID-19 on the Guillain–Barré Syndrome Incidence
Kopańko, M., Zabłudowska, M., Zajkowska, M., Gudowska-Sawczuk, M., Mucha, M., & Mroczko, B. (2024) · Biomedicines · doi:10.3390/biomedicines12061248 · Cited by 7
Humoral waning kinetics against SARS-CoV-2 is dictated by disease severity and vaccine platformPreprint
Tong, X., Kellman, B. P., Avendaño, M. J., Mendu, M., Hsiao, J. C., Serrano, E. F., García‐Salum, T., Muena, N. A., Pardo‐Roa, C., Morales, M., et al. (2024) · medRxiv · doi:10.1101/2024.10.17.24315607 · Cited by 5
“Although differences in antibody titers and neutralization afforded by these two vaccines have been documented ( 24, 25 ), it remains to be investigated whether the functional antibody responses induced by these two vaccine platforms decline differentially over time and whether heterologous…”
BackgroundBester, J. C. (2022) · Journal of Bioethical Inquiry · doi:10.1007/s11673-022-10182-y · Cited by 6
“& Vaccination decreases risk of COVID-19 death >90 per cent (Benenson et al. 2021; Haas et al. 2021; Krause et al. 2021; McDonald et al. 2021; Polack et al. 2020; Thomas et al. 2021; Self et al. 2021).”
BackgroundInfluentialHelle, F., Moyet, J., Demey, B., François, C., Duverlie, G., Castelain, S., Bloch, F., & Brochot, É. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.11.086 · Cited by 6
Next Steps for Efficacy Evaluation in Clinical Trials of COVID-19 Vaccines
Jiang, H.-D., Zhang, L., Li, J., & Zhu, F. (2021) · Engineering · doi:10.1016/j.eng.2021.04.013 · Cited by 4
“S [3,4,8,11], this data is not solid, as the small number of seniors enrolled in the trial and the protective efficacy of other candidate vaccines in seniors were not estimated.”
Modelling the impact of extending dose intervals for COVID-19 vaccines in CanadaPreprint
Nam, A., Ximenes, R., Yeung, M. W., Mishra, S., Wu, J., Tunis, M. C., & Sander, B. (2021) · medRxiv · doi:10.1101/2021.04.07.21255094 · Cited by 5
“For both vaccines, protection began 14 and 7 days after administrating the first and second doses, respectively.(6,7) We used a mild waning .”
MethodBosch, A. M., Guzman, H. V., & Pérez, R. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00460 · Cited by 10
Safir, A., Samuelov, L., Sprecher, E., Daniely, D., & Artzi, O. (2022) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.15260 · Cited by 7
Díaz‐Menéndez, M., Calle, F., Montejano, R., Arsuaga, M., Jiménez-González, M., Pérez-Blanco, V., Marcelo, C., Vasquez-Manau, J., Lázaro, F., & Arribas, J. R. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.06.003 · Cited by 6
Hetrick, B., He, S., Chilin, L. D., Dabbagh, D., Alem, F., Narayanan, A., Luchini, A., Li, T., Liu, X., Copeland, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.22.423965 · Cited by 6
Nogawa, S., Kanamori, H., Tokuda, K., Kawafune, K., Chijiiwa, M., Saito, K., & Takahashi, S. (2021) · medRxiv · doi:10.1101/2021.11.30.21267043 · Cited by 5
Implications of COVID-19 Pandemic on Pregnancy: Current Status and Controversies
Greenberg, G. C., Vishwakarma, N., Tirupattur, M. P., Sprague, H. M., & Katwa, L. C. (2023) · COVID · doi:10.3390/covid3060062 · Cited by 5
Scotto, R., Buonomo, A. R., Zumbo, G., Fusco, A. D., Esposito, N. D. P., Filippo, I. D., Nobile, M., Pinchera, B., Moriello, N. S., Villari, R., et al. (2022) · Vaccines · doi:10.3390/vaccines10111895 · Cited by 4
“efficacy and safety profiles [5,6] significantly contributing to reducing the impact of the pandemic in terms of severe disease incidence, hospitalizations and deaths [7].”
BackgroundSokal, A., Spaeth, G. B., Fernández, I., Broketa, M., Azzaoui, I., Selle, A. D. L., Vandenberghe, A., Fourati, S., Roeser, A., Meola, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.17.448459 · Cited by 5
“They were shown to be safe, highly effective to prevent infection and to control disease severity (Baden et al., 2021; Dagan et al., 2021; Polack et al., 2020).”
BackgroundEvaluation of possible COVID-19 reinfection in children: A multicenter clinical study
Erbaş, İ. C., Keleş, Y. E., Erdeniz, E. H., Yılmaz, A. T., Yeşil, E., Çakıcı, Ö., Akça, M., Ulu, N. K., Dinç, F., Çiftdoğan, D. Y., et al. (2023) · Archives de Pédiatrie · doi:10.1016/j.arcped.2023.01.008 · Cited by 7
“Although the protection against COVID-19 after recovering from this infection seems to be almost similar to the efficacy of vaccination, an exact comparison cannot be made due to differences in study designs and study populations [41,42].”
BackgroundTanaka, T., Tashiro, M., Ota, K., Fujita, A., Sawai, T., Kadota, J., Fukuda, Y., Sumiyoshi, M., Ide, S., Tachikawa, N., et al. (2023) · Medicine · doi:10.1097/md.0000000000034858 · Cited by 5
Kawamura, Y., Yoshimachi, F., Nanao, T., Kasai, S., & Ikari, Y. (2022) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2022.06.012 · Cited by 6
“To combat the pandemic, the development of vaccines against COVID-19 was accelerated; of these, the efficacy of mRNA formulations was demonstrated and has been focused on in many countries [2,3].”
Lin, J., Law, R., Korosec, C. S., Zhou, C. Y., Koh, W. H., Ghaemi, M. S., Samaan, P., Ooi, H. K., Yue, F., Gingras, A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.18.476864 · Cited by 5
COVID-19 pandemic sentiment and stock market behavior: evidence from an emerging market
Debata, B., Ghate, K., & Renganathan, J. (2021) · Review of Behavioral Finance · doi:10.1108/rbf-05-2021-0083 · Cited by 8
Predicting clinical outcomes of SARS-CoV-2 infection during the Omicron wave using machine learning
Cogill, S., Nallamshetty, S., Fullenkamp, N. K., Heberer, K. R., Lynch, J. A., Lee, K. M., Aslan, M., Shih, M., & Lee, J. S. (2024) · PLoS ONE · doi:10.1371/journal.pone.0290221 · Cited by 4
“Finally, the model results were most relevant to Omicron variants and sub-variants and may not be relevant to other pathogenetic SARS-CoV-2 variants.”
ResultHELFGOTT, D. C., Racine‐Brzostek, S., Short, K. J., Zhao, Z., Christos, P. J., Nino, I., Niu, T., Contreras, J., Ritchie, E. K., Desai, P. M., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2131414 · Cited by 5
“The BNT162b2 (BioNTech/Pfizer) and mRNA-1273 (Moderna) vaccines were demonstrated in clinical trials to have clinical efficacies of 95% (2) and 94% (3) respectively in immunocompetent adults.”
BackgroundAnderegg, N., Althaus, C. L., Colin, S., Hauser, A., Laube, A., Mäusezahl, M., Wagner, M., Zaffora, B., & Riou, J. (2022) · Swiss Medical Weekly · doi:10.4414/smw.2022.w30163 · Cited by 5
Preparation, characterization, and stability of lipid nanoparticles including unsaturated lipids
Park, Y., & Park, J.-W. (2023) · Tenside Surfactants Detergents · doi:10.1515/tsd-2023-2544 · Cited by 5
Hilty, M. P., Moser, A., David, S., Wendel‐Garcia, P. D., Capaldo, G., Keiser, S., Fumeaux, T., Guerci, P., Montomoli, J., Boeckel, T. P. V., et al. (2021) · Swiss Medical Weekly · doi:10.4414/smw.2021.20553 · Cited by 6
Severity of Omicron Subvariants and Vaccine Impact in Catalonia, Spain
de Rioja, V. L., Basile, L., Perramon‐Malavez, A., Martínez-Solanas, É., López, D., Maestro, S. M., Coma, E., Avilés, F. F., Prats, C., Mendioroz, J., et al. (2024) · Vaccines · doi:10.3390/vaccines12050466 · Cited by 7
Casas, I., & Mena, G. (2021) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2021.03.006 · Cited by 7
Lyapunov Stability Analysis of Covid-19 SIRV Model
Mahayana, D. (2022) · IEEE International Colloquium on Signal Processing & Its Applications (CSPA) · doi:10.1109/cspa55076.2022.9781865 · Cited by 4
A systems biology approach to define SARS-CoV-2 correlates of protection
Brady, C., Tipton, T., Carnell, O. T., Longet, S., Gooch, K. E., Hall, Y., Salguero, J., Tomić, A., & Carroll, M. W. (2025) · npj Vaccines · doi:10.1038/s41541-025-01103-2 · Cited by 10
Considerations on SARS-Cov-2 vaccines in patients with autoimmune blistering diseases
Cozzani, E., Gasparini, G., Sticchi, L., et al. (2021) · European Journal of Dermatology · doi:10.1684/ejd.2021.4043 · Cited by 5
Shah, H., Halpern, J., Watane, G. V., et al. (2021) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003757 · Cited by 5
Sieber‐Schäfer, F., Binder, J., Münchrath, T., Steinegger, K. M., Jiang, M., Winkeljann, B., Frieß, W., & Merkel, O. M. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c12694 · Cited by 6
Sintusek, P., Buranapraditkun, S., Khunsri, S., Saengchaisukhonkit, V., Vichaiwattana, P., Srimuan, D., Thongmee, T., & Poovorawan, Y. (2022) · Vaccines · doi:10.3390/vaccines10081324 · Cited by 6
“Due to its high efficacy and favorable safety profile, the BNT162b2 vaccine was authorized for use in adults by the Food and Drug Administration (FDA) in December 2020, a year after the start of the pandemic [4].”
BackgroundStrong, L. E., Middendorf, I., Turner, M., Edwards, D. K., V, Sama, V., Mou, J., & Adams, K. C. (2021) · JMIR Human Factors · doi:10.2196/29234 · Cited by 5
Ssemaganda, A., Nguyen, H. M., Nuhu, F., Jahan, N., Card, C. M., Kiazyk, S. A. K., Severini, G., Keynan, Y., Su, R., Ji, H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.07.442971 · Cited by 5
Design of messenger RNA vaccines based on lipid-polymer hybrid nanoparticles
Baghel, S. S., Lokras, A. G., Dias, B. A., Landry, M. R., Cérda, S. L., Wadhwa, A., Herrera‐Barrera, M., Thakur, A., Rades, T., Franzyk, H., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114385 · Cited by 7
Selby, L. M., Hewlett, A. L., Cawcutt, K. A., Wood, M. G., Balfour, T., Rupp, M. E., & Starlin, R. C. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.193 · Cited by 4
Spinelli, M. A., Johnson, M. O., Lisha, N. E., et al. (2024) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003466 · Cited by 5
Salehi, M., Darazam, I. A., Nematollahi, A., Alimohammadi, M., Pouya, S., Alimohammadi, R., Khajavirad, N., Porgoo, M., Sedghi, M., Sepahi, M. M., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112192 · Cited by 5
Ethical issues in placebo-controlled trials of COVID-19 vaccines
de Oliveira, A. C. A. X., & Paumgartten, F. J. R. (2021) · Cadernos de Saúde Pública · doi:10.1590/0102-311x00007221 · Cited by 7
New drug: BNT162b2 vaccine for prevention of COVID-19
(2021) · Australian Prescriber · doi:10.18773/austprescr.2021.008 · Cited by 5
Frölke, S. C., Bouwmans, P., Messchendorp, A. L., Vervoort, J. P. M., Abrahams, A. C., de Vries, A. P. J., Nieuwkerk, P. T., Hemmelder, M. H., Gansevoort, R. T., Hilbrands, L. B., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102103 · Cited by 6
Zhao, G., Zhang, Z., Ding, Y., Hou, J., Liu, Y., Zhang, M., Sui, C., Wang, L., Xu, X., Gao, X.-M., et al. (2023) · Vaccines · doi:10.3390/vaccines11030513 · Cited by 4
“Various COVID-19 vaccines available for human use are designed based on the wild-type of SARS-CoV-2, including the widely used mRNA vaccines BNT162b2 (Pfizer) [7,17] and mRNA-1273 (Moderna) [18,19] in Europe and North”
MethodVaccinated kidney transplant recipients are yet not sufficiently protected against COVID-19
Messchendorp, A. L., & Gansevoort, R. T. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad127 · Cited by 5
“The pivotal phase 3 registration trials with the messenger RNA (mRNA) vaccines reported an efficacy of 95% for the BNT162b2 (BioNTech/Pfizer) vaccine and 94% for the mRNA-1273 (Moderna) vaccine [ 4 , 5 ].”
BackgroundShadmani, F. K., Moradi, G., Naghipour, M., Asadi, F. T., Ahmadi, A. R., Mirahmadizadeh, A., Haghdoost, A. A., Mesgarpour, B., Zahraei, S. M., Goya, M. M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1420651 · Cited by 5
Wagenhäuser, I., Reusch, J., Gabel, A., Mees, J., Nyawale, H. A., Frey, A., Lâm, T., Schubert‐Unkmeir, A., Dölken, L., Kurzai, O., et al. (2023) · Journal of Sleep Research · doi:10.1111/jsr.13929 · Cited by 10
“…that the COVID-19 pandemic has now been ongoing for more than 3 years (Wu et al., 2020), and that novel mRNA-based vaccines (Baden et al., 2020; Polack et al., 2020) have been administered to billions of individuals worldwide, it is surprising that the impact of sleep and mental health on the…”
BackgroundLevi, M. L., McMillan, D., Dhandha, V. H., Allan, J., & D'ercole, F. (2021) · Perioperative Care and Operating Room Management · doi:10.1016/j.pcorm.2021.100220 · Cited by 7
Ayaz, H., Çelik, M. H., Koytak, H. Z., & Yanik, I. E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0308122 · Cited by 9
Zerankeshi, M. M., Charland, D. J., Donnelly, K. A., Nash, G. T., Shi, J., Patil, D. N., Ennis, J., Rodriguez, K. G., Corba, S., Wambolt, N. A., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c22170 · Cited by 6
R, S. K. D., Srividya, J., Patel, A. E., & Vidya, R. (2021) · medRxiv · doi:10.1101/2021.11.21.21262716 · Cited by 5
“[22] This has been termed the nocebo effect, which results from enhanced anticipation of negative outcomes from an intervention .”
Ralli, M., De‐Giorgio, F., Soave, P. M., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100053 · Cited by 5
Antiviral Therapeutics for Emerging Viruses
Ogidi, O. I., Aye, T., & Felagha, I. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-9276-8.ch006 · Cited by 5
Gentili, V., Bortolotti, D., Morandi, L., Rizzo, S., Schiuma, G., Beltrami, S., Casciano, F., Papi, A. A., Contoli, M., Zauli, G., et al. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807156 · Cited by 5
Microcondensate‐Mediated Intracellular Infusion of mRNA Across the Plasma Membrane
Kawaguchi, Y., Kikkawa, A., Kimura, S., Abe, H., & Futaki, S. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202512139 · Cited by 7
Single-pixel imaging flow cytometry for biomedical research
Kanno, H., Liu, Z., Sato, R., Endo, H., Niizuma, K., & Goda, K. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00401-5 · Cited by 6
“…vaccines developed by Pfizer-BioNTech and Moderna demonstrated strong efficacy in preventing infection and in reducing the risk of severe disease [120, 121], rare side effects, such as myocardial infarction and thrombotic events, raised concerns about their potential impact on platelet function…”
Kim, Y., Kim, J., & Li, Y. (2023) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2023.05.024 · Cited by 6
Hamza, M. S., Tikamdas, R., Baghdady, N. S. E., Sayed, M., ElBarazi, A. S., Badary, O. A., & Elmazar, M. M. (2022) · Vaccines · doi:10.3390/vaccines10060846 · Cited by 5
“These findings are highly consistent with the results reported in phase III clinical trials and vaccine fact sheets, and they are mostly reported for those who received the second dose [31,32].”
ResultDelbrueck, M., Hoehl, S., Toptan, T., Schenk, B., Grikscheit, K., Metzler, M., Herrmann, E., & Ciesek, S. (2021) · medRxiv · doi:10.1101/2021.11.09.21266110 · Cited by 6
Dudley, H. M., O'Mara, M., Auma, A. W. N., Gong, J. D., Ross, Y., Gurevich, N., Carbone, S., Reihs, A., Nguyen, Y., McComsey, G. A., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.08.033 · Cited by 6
MacMahon, M., Hwang, W., Yim, S., MacMahon, E., Abraham, A., Barton, J., Tharmakulasingam, M., Bilokon, P., Gaddi, V. P., & Han, N. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101387 · Cited by 6
“Despite several highly efficacious vaccines being deployed against SARS-CoV-2[10]– [13], the pandemic is still ongoing.”
BackgroundGill, R., Rizvi, M., Sadiq, M. S., et al. (2022) · BMJ Case Reports · doi:10.1136/bcr-2021-245749 · Cited by 5
Immunization with an mRNA DTP vaccine protects against pertussis in rats
Bitzer, G. J., Fitzgerald, N. A., DeJong, M. A., Cunningham, C., Chapman, J. A., Boehm, D. T., Pyles, G. M., Huckaby, A. B., Miller, S. J., Dublin, S. R., et al. (2024) · Infection and Immunity · doi:10.1128/iai.00520-23 · Cited by 7
“…mRNA vaccines against SARS-CoV-2 showed firsthand how beneficial this type of vaccine could be in our future fights against pathogenic microbes (19–21). mRNA vaccine technology allows for the development of vaccines that have the safety profile of aP formulations paired with the immune response…”
BackgroundWalsh, C. T. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00584 · Cited by 5
Postvaccination anaphylaxis and mRNA‐based SARS‐CoV‐2 vaccines—Much ado about nothing?
Marčec, R., & Likić, R. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14763 · Cited by 4
Smart Nanoparticles in Biomedicine: An Overview of Recent Developments and ApplicationsPreprint
Campora, S., & Ghersi, G. (2021) · Preprints.org · doi:10.20944/preprints202102.0619.v1 · Cited by 5
Chemically modified tRNA enhances the translation capacity of mRNA rich in cognate codons
Dong, L., Wang, J., & Xia, Q. (2025) · Nature Communications · doi:10.1038/s41467-025-62981-7 · Cited by 8
Mishra, T. K., Joshi, G., Kumar, A., Dalavi, R., Pandey, P., Shukla, S., Mishra, R. K., & Chande, A. G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.04.463028 · Cited by 5
Erice, A., Prieto, L., & Caballero, C. (2023) · Vaccines · doi:10.3390/vaccines11121835 · Cited by 5
“…conducted before the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants Delta (B.1.617.2) and Omicron (B.1.1.529), two doses of the mRNA vaccine BNT162b2 (Comirnaty, BioNTech Manufacturing GmbH, Mainz, Germany) were 95% protective against symptomatic infection [1].”
BackgroundInfluentialNanoparticle-Based Vaccines against Zoonotic Viruses: A Review
Zhang, X., & Cui, Z. (2023) · Zoonoses · doi:10.15212/zoonoses-2023-0018 · Cited by 6
Nucleic acid vaccines: A taboo broken and prospect for a hepatitis B virus cure
Tsounis, E. P., Mouzaki, Α., & Triantos, C. K. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i41.7005 · Cited by 5
Respiratory virus mRNA vaccines: mRNA Design, clinical studies, and future challenges
Zheng, L., & Feng, H. (2025) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70018 · Cited by 9
“…the onset of the COVID-19 pandemic, Pfizer (US) and BioNTech (Germany) jointly developed the BNT162 vaccine, 8 while Moderna developed mRNA-1273 9,10 On May 31, 2024, Moderna announced that its RSV mRNA vaccine, mRESVIA, received U.S. Food and Drug Administration's (FDA) approval, 11,12…”
Moving Forward from the COVID-19 Pandemic: Needed Changes in Movement Disorders Care and Research
Valdovinos, B. Y., Modica, J. S., & Schneider, R. B. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01178-7 · Cited by 6
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.